C
Cybrexa Therapeutics
A New Haven, CT-based cancer therapeutics company
About Cybrexa Therapeutics
Cybrexa Therapeutics, established in 2016, is a clinical-stage biotechnology firm operating from New Haven, Connecticut. The company was co-founded by Per H. Hellsund, who serves as President and CEO, and Ranjit Bindra, MD, PhD, a physician-scientist from the Yale School of Medicine who acts as Chief Scientific Advisor. Hellsund brings a track record of executive leadership from prior technology and life science ventures, including the successful development and sale of CyVek to Bio-Techne. Bindra's background as a practicing oncologist and researcher in CNS tumors provides deep clinical and scientific expertise that directly informs the company's direction. As a privately held entity, Cybrexa has secured approximately $118 million in capital through eight funding rounds, including a $40.2M Series C in June 2022, backed by investors such as Connecticut Innovations, HighCape Capital, and Elm Street Ventures.
The company's core focus is on developing a new class of cancer therapies utilizing its proprietary alphalex™ peptide-drug conjugate (PDC) platform. This technology is designed for the targeted, intracellular delivery of potent anti-cancer agents directly into tumor cells. A key differentiator of the alphalex™ platform is its antigen-independent targeting mechanism. Instead of relying on specific protein markers on a cancer cell's surface, it leverages the universally acidic tumor microenvironment—a phenomenon known as the Warburg Effect. The platform uses a pH-Low Insertion Peptide (pHLIP®), which was developed at Yale University and the University of Rhode Island, that changes its structure in low-pH conditions. This change triggers the peptide to insert itself into the cancer cell membrane, delivering a linked cytotoxic payload directly into the cell while largely sparing healthy tissue, which exists at a normal pH. This mechanism aims to improve the therapeutic index of powerful drugs, enhancing efficacy while minimizing systemic toxicity.
Cybrexa's lead clinical candidate is CBX-12, an alphalex™ conjugate of exatecan, a highly potent topoisomerase I inhibitor. CBX-12 has completed a Phase 1 study where it demonstrated a manageable safety profile and promising anti-tumor activity across a range of advanced or metastatic solid tumors. Notably, clinical benefit was observed in patients with ovarian, breast, non-small cell lung cancer (NSCLC), and colorectal cancers. Following these results, a Phase 2 trial for CBX-12 in patients with platinum-resistant ovarian cancer was initiated in late 2024. The company is also planning further Phase 2 studies for CBX-12 as both a monotherapy and in combination with other agents for various solid tumors starting in 2025. Beyond its lead program, Cybrexa is advancing its pipeline with candidates like CBX-15, which utilizes MMAE as its payload and is expected to enter clinical trials in 2025.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 62.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Cybrexa Therapeutics is 1.2K monthly website visits, down 25% over the last three months. Cybrexa Therapeutics's team declined 15.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cybrexa Therapeutics in the New Haven ecosystem
The Cybrexa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Connecticut Innovations- HPHighCape Partners
- EVElm Street Ventures
Series B and later1 investor entered at this stage
Advantage Capital
Other known investors3 additional known investors
Yale University
Small Business Innovation Research
Yale Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cybrexa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cybrexa Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








